Filing Flows › Consumer Staples › United Guardian (UG)
United Guardian (UG) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 11, 2026 · United Guardian (UG) Q2 2026 earnings results →
Q2 2026 Revenue up 10% year over year to $3.1M · 23¢ of every $1 of revenue kept as net profit · operating margin 24.3%
United Guardian made $3.1M in Q2 2026 (+10% Y/Y): Pharmaceuticals $1.5M, Cosmetic Ingredients $1.3M, Medical $353K. Operating margin 24.3%, net earnings $729K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 11, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $3.1M in Q2 2026, up 10% year over year and up 8% from the previous quarter. Pharmaceuticals was the largest line at 47% of revenue. Cosmetic Ingredients added $390K year over year (up 44%), 144% of the total change. Medical declined 28%.
Operating profit was $754K, a 24.3% margin (down 0.2 points year over year). Of the extra revenue versus Q2 2025, 22% reached operating profit, below the 25% margin then. Total costs grew 10% against revenue growth of 10%. The fastest-growing cost line was Cost of revenue (+17%). Net earnings were $729K, up 16% year over year. The effective tax rate was 20.6%.
Operating cash flow was $1.5M (up 401% year over year), 209% of net earnings. Non-cash charges added back $29K of depreciation and amortization. Working capital and other items added $762K. Capital expenditures of $19K left free cash flow of $1.5M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 11, 2026 | $3.1M | +10% | 24.3% | $729K | $1.5M |
| Q1 2026 | 10-Q | May 12, 2026 | $2.9M | +16% | 22.4% | $819K | $605K |
| Q4 2025 | 10-K | Mar 27, 2026 | $3.0M | +20% | 24.4% | $650K | $330K |
| Q3 2025 | 10-Q | Nov 6, 2025 | $2.3M | -26% | 9.5% | $268K | $1.0M |
| Q2 2025 | 10-Q | Aug 8, 2025 | $2.8M | -16% | 24.5% | $627K | $303K |
| Q1 2025 | 10-Q | May 13, 2025 | $2.5M | -24% | 24.6% | $561K | $322K |
| Q4 2024 | 10-K | Mar 21, 2025 | $2.5M | -5% | 22.5% | $504K | $269K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About United Guardian
United-Guardian, Inc. (“Company”) is a Delaware corporation that, through its Guardian Laboratories division, manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients and a line of healthcare products including pharmaceuticals and medical lubricants. The Company conducts various research and development (“R&D”) activities. The Company’s R&D department primarily develops new and unique specialty cosmetic and sexual wellness ingredients using natural and environmentally friendly raw materials, which is a priority for many of our cosmetic customers. The R&D department also modifies, refines, and expands the uses for existing products, with the goal of further developing the markets that our products are used in. All the products that the Company markets, except for Renacidin ® , are produced at our facility in Hauppauge, New York.
In its own words, from its 10-Q, filed May 12, 2026.
United Guardian against its Perfumes, Cosmetics & Other Toilet Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +10% against the peers' median +3%. Operating margin: 24.3% against the peers' median 11.0%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| UG United Guardian | Q2 2026 | $3.1M | +10% | 24.3% |
| CL Colgate Palmolive | Q3 2026 | $5.4B | +5% | 20.3% |
| KVUE Kenvue | Q3 2026 | $3.9B | +3% | 18.2% |
| EL Estee Lauder Companies | Q1 FY27 | $3.7B | +7% | 11.0% |
| COTY Coty | Q1 FY27 | $1.6B | -1% | 11.0% |
| EPC Edgewell Personal Care | Q3 FY26 | $570M | +2% | 4.4% |
| ELF e.l.f. Beauty | Q2 FY27 | $521M | +51% | 10.1% |
| IPAR Interparfums | Q3 2026 | $430M | 0% | 27.4% |
| SLSN Solesence | Q2 2026 | $15.3M | -25% | 0.8% |
Source: United Guardian 10-Q on SEC EDGAR · CIK 101295 · Perfumes, Cosmetics & Other Toilet Preparations
13F: who owns UG and who is buying
More on UG
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results
- United Guardian operating margin by quarter
- United Guardian net income by quarter
- United Guardian free cash flow by quarter
- United Guardian R&D spending by quarter
- United Guardian capital expenditures by quarter
- United Guardian Pharmaceuticals revenue by quarter
- United Guardian Cosmetic Ingredients revenue by quarter
- United Guardian Medical revenue by quarter